View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 13, 2021updated 19 Jul 2022 12:49pm

Healthcare sector could take more than three years to stabilise in the event of no-deal Brexit: Poll

Until the signing of the new trade deal in December 2020, speculation was high on the adverse impact of a no-deal Brexit on the UK healthcare.

Until the signing of the new trade deal in December 2020, speculation was high on the adverse impact of a no-deal Brexit on the UK healthcare.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

GlobalData has conducted a poll to assess the anticipated time for the UK to stabilise its healthcare industry post Brexit in the case of no-deal Brexit.

Analysis of the results shows that that it will take more than three years for the UK healthcare sector to stabilise, as opined by a majority 56% of the respondents. While 35% of the respondents opined that it will take more than five years to stabilise, 21% opined that it will take three years to less than five years.

Timeframe to stabilise the UK’s healthcare industry post Brexit

Further, 24% of the respondents opined that the UK healthcare industry will take less than one year to stabilise and the remaining 20% opined that it will take one year to less than three years.

The analysis is based on 412 responses received from the readers of Pharmaceutical Technology, a Verdict network site, between 01 September 2020 and 04 January 2021.

No-deal Brexit and the UK healthcare sector

The multiple potential outcomes of a no-deal Brexit made it extremely difficult to forecast how long it would take for the healthcare industry to stabilise, according to GlobalData. The UK trades approximately 40% of its exports to the EU countries, a majority of which comprise healthcare-associated industries.

A no-deal Brexit, therefore, would have adversely impacted the country’s exports as well as imports, adds GlobalData. Staffing shortages at the National Health Service (NHS), especially under the current pandemic situation, and shortages and price rise of vital medicines were some of the immediate implications predicted by The King’s Fund, an independent charitable organisation.

The uncertainties led companies including AstraZeneca and GlaxoSmithKline, and patients to stockpile medications, especially those imported. Despite stockpiling and plans to create new supply routes, a no-deal Brexit could have created significant regulatory hurdles for vital supplies, adds The King’s Fund.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology